Could a blood pressure drug slow a leaky heart valve?
NCT ID NCT07539298
First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times
Summary
This study tests whether valsartan, a common blood pressure drug, can slow the worsening of atrial functional mitral regurgitation (a leaky heart valve) in 50 adults with normal heart pumping function. Participants take either valsartan or a placebo twice daily for 12 months, with regular heart imaging and safety checks. The goal is to see if the drug reduces valve damage and improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Valsartan (a blood pressure medication)
- What this could lead to
- If it works, this could point toward a way to slow the progression of atrial mitral regurgitation without surgery.
- What could go wrong
- This is a small pilot study with only 50 participants, so results may not apply to everyone. Valsartan may not slow the condition and could cause side effects like low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. No evidence of mitral organic disease 2. At least moderate left atrial dilatation (left atrial volume index ≥34 mL/m²) 3. Normal (≥ 50%) left ventricular ejection fraction and 4. At least moderate MR grade by multiparametric assessment. Exclusion Criteria: 1. Inability to provide informed consent 2. Indication for or ongoing treatment with ACEI/ARB 3. History of hypotension 4. Hypertension (\>140/90 mmHg) \* 5. Planned cardiac surgery (CABG or valve) 6. Ongoing or planned pregnancy 7. Chronic renal failure with eGFR \< 30 mL/min/1.73m2 8. Neurocognitive disorder 9. History of hyperkalemia 10. Medication interacting with valsartan
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial functional mitral regurgitation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut universitaire de cardiologie et de pneumologie de Québec-ULaval
RECRUITINGQuébec, Quebec, G1V4G5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.